(RGEN) Repligen - Ratings and Ratios

Repligen Corporation, a leader in life sciences, specializes in bioprocessing technologies and systems, serving clients across North America, Europe, Asia Pacific, and globally. Their product portfolio includes Protein A ligands, essential in affinity chromatography, and cell culture growth factors. The company offers chromatography solutions like OPUS columns for biologic purification and smaller-scale columns for process development. Filtration products include XCell ATF systems for cell retention and TangenX cassettes for biologic processing. They also provide process analytics tools under brands like SoloVPE. Repligen serves biopharmaceutical firms, researchers, and contract manufacturers. Their collaboration with Navigo Proteins enhances their ligand development capabilities. Founded in 1981, they are headquartered in Waltham, Massachusetts.

ticker: RGEN, exchange: NASDAQ, type: common stock, country: USA, industry: Life Sciences Tools & Services.

average volume: 860,156, last price: $145.23, SMA20: $127.55, SMA50: $141.32, SMA200: $145.70, ATR: 9.00.

market cap: $7.42B, forward P/E: 76.92, P/B: 3.76, P/S: 11.70, RoE: -1.44.

3-month forecast: RGEN may test resistance at $150, supported by SMA200 near $145.70. A breakout could target $160, with ATR suggesting $9 fluctuations. If support at $141.32 fails, a drop to $135 is possible. High P/S indicates growth expectations despite negative RoE.